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Abstract 
 
The tumour control probability (TCP) is a formalism derived to compare various 
treatment regimens of radiation therapy, defined as the probability that given a prescribed 
dose of radiation, a tumour has been eradicated or controlled. In the traditional view of 
cancer, all cells share the ability to divide without limit and thus have the potential to 
generate a malignant tumour. However, an emerging notion is that only a sub-population 
of cells, the so-called cancer stem cells (CSCs), are responsible for the initiation and 
maintenance of the tumour. A key implication of the CSC hypothesis is that these cells 
must be eradicated to achieve cures, thus we define TCPS as the probability of eradicating 
CSCs for a given dose of radiation. A cell surface protein expression profile, such as 
CD44high/CD24low for breast cancer, is often used as a biomarker to monitor CSCs 
enrichment. However, it is increasingly recognized that not all cells bearing this 
expression profile are necessarily CSCs, and in particular early generations of progenitor 
cells may share the same phenotype. Thus, due to the lack of a perfect biomarker for 
CSCs, we also define a novel measurable TCPCD+, that is the probability of eliminating or 
controlling biomarker positive cells. Based on these definitions, we use stochastic 
methods and numerical simulations to compare the theoretical TCPS and the measurable 
TCPCD+. We also use the measurable TCP to compare the effect of various radiation 
protocols. 
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Introduction 
 
Radiotherapy has become a primary vehicle for cancer therapy, and its continued use as 
an effective therapeutic and palliative treatment can only be justified if the risks of 
associated side effects that may be incurred are minimized. Theoretically, this can be 
posed as an optimization problem, where the risk-to-benefit function for the radiation 
dosing and scheduling must be optimized. In this work, one key element of this function, 
the attainable benefit from the treatment, is examined. Classically, the tumour control 
probability (TCP) has been used as a tool in radiotherapy to measure the probability that 
the goal of the treatment - the elimination of all clonogenic cells - has been achieved 
(Munro and Gilbert 1961). Using data in the form of survival fraction curves (which 
carry information of the proportion of cells that survive a specified dose of radiation), as 
a probability model for radiation-induced individual clonogenic cell death, the TCP 
computes the probability of tumour eradication by taking into account factors such as cell 
proliferation between radiation treatment fractions, and natural cell death rates. 
 
The traditional view of cancer asserts that all cells in a malignant tumour are clonogenic, 
with genetic and epigenetic differences. An emerging hypothesis is the notion that many 
cancers are driven by cancer stem cells (CSCs), a subpopulation of cells that have the 
capacity to proliferate indefinitely and hence to drive and maintain tumour growth. 
Existence of CSCs has been firmly identified in leukaemia (Bonnet and Dick 1997), and 
more recently in many solid tumours including breast cancer (Al-Hajj et al. 2003) and 
brain tumours (Singh et al. 2003, Singh et al. 2004).  
 
Moreover, other works have hypothesized (and demonstrated in the context of 
hematopoietic cancers) the existence of a hierarchy of cells at various stages of 
differentiation comprising a tumour, starting with stem cells differentiating into 
progenitor cells, which differentiate into mature cells. A main implication of the CSC 
hypothesis is that CSCs can generate all of the cells within a given tumour that lack 
cancer propagating potential (non-CSCs), and also that the CSCs must be eradicated to 
control the tumour (Nguyen et al. 2012). Hence, we define TCPS as the probability of 
eradicating or controlling CSCs for a given total dose of radiation.  
 
Like normal stem cells, cell surface protein expression profiles are frequently used to 
identify and isolate CSCs. This includes CD34highCD38low for leukaemia, CD133+ for 
brain tumours and CD44highCD24low for breast tumours. However, there is growing 
evidence that not all cells bearing this expression profile are necessarily CSCs (see 
Nguyen et al. 2012 and the references therein). Considering CSCs as the apex of the 
hierarchy, they can undergo either symmetric or asymmetric divisions to replenish the 
CSC pool and to generate progenitor cells with limited proliferative potential and low 
tumorigenic potential. Typically, an early progenitor will divide into later (more mature) 
progenitors, undergoing only several rounds of self-renewing cell division before 
terminally differentiating. Emerging evidence supports the conclusion that early 
generations of progenitor cells share the same biomarker. Thus, we assume that the cell 
surface protein expression (we use the general notation CD+) is shared by CSCs and the 
first three generations of progenitor cells (Turner and Kohandel 2010, 2012), Figure 1. 
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Thus, we also define a TCPCD+ as the probability of eliminating or controlling biomarker 
positive (CD+) cells.  
 
A feature of the CSC hypothesis is its unidirectional nature. However, recent studies have 
supported the existence of considerable plasticity between the non-CSC and CSC 
populations, suggesting bidirectional conversions between these two compartments 
(Marjanovic et al. 2013). Such dedifferentiation may arise due to stochastic acquisition of 
genetic or epigenetic mutations in genes promoting the CSC-like state (for example, 
MBI1). Experimental studies have also shown that the reverse process can occur through 
the epithelial to mesenchymal transition (Mani et al. 2008, Chaffer et al. 2011). In this 
paper, we assume that dedifferentiation can be ignored during radiation treatment and 
consider a solely unidirectional hierarchy for the CSC hypothesis; future works in this 
area may include an analysis of how the rate of dedifferentiation impacts the TCP.  
 
On the theoretical side, several models have been developed to study the TCP (see Zaider 
and Hanin 2001, for a review). A simplified model for the TCP can be computed based 
on binomial statistics, whereby we may define a success to be a cell death, and then the 
tumour control probability is defined to be the probability that there are 0n  successes, 
where 0n  is the total clonogenic cell population. This model neglects to include cell 
proliferation between fractions, as well as stochastic effects. A second model that has 
been studied extensively is based on Poisson statistics, used to approximate the stochastic 
process of radiation-induced cell killing. In this model, deterministic differential 
equations are formulated that account for cell growth and death due to both natural 
causes, as well as radiation, and then the probability of tumour control is given by a 
Poisson distribution, whose mean is the solution to the deterministic equation. A third 
model that has been formulated that describes the stochastic effects of radiation-induced 
cell death with great accuracy is the Zaider-Minerbo TCP model (Zaider and Minerbo 
2000), in which the stochastic processes underlying cell birth and death are formalized, 
and used to define a master equation. Then, via a generating function approach, this 
master equation is transformed into a partial differential equation, which can 
subsequently be solved for the TCP. Recent works have concentrated on accounting for 
cell cycle effects on the potency of radiotherapy, by accounting for the extra 
radioresistance conferred by the presence of quiescent (non-active) tumour cells (Maler 
and Lutscher 2010, Dhawan et al. 2013).  
 
Despite all of the extensions to the TCP that can be found in the literature, the primary 
argument leveled against the TCP, that it is not a measurable quantity during therapy, still 
holds.  Because tumour control is only achieved when the entire clonogenic cell 
population has been eliminated, in order to experimentally verify this, it would be 
necessary to examine every remaining tumour cell for clonogenicity. The extension to the 
TCP that is presented here accounts for the presence of cancer stem cells, and because 
(barring effects of dedifferentiation during radiation) the eradication of cancer stem cells 
effectively implies tumour control, the TCPS is defined as the control of the cancer stem 
cell population only. In addition, due to the lack of a perfect biomarker, we define a 
second variant of the TCP, called TCPCD+ defined only as the control of biomarker-
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positive cells. Moreover, the model used to describe stem cells in this work is a 
hierarchical one, which has not been previously considered in the literature. 
 
We use stochastic methods, combined with analytical and computational techniques, to 
calculate TCPS and TCPCD+. We show the relationship between these two variants of the 
TCP under different scenarios. Thus, we essentially depict the relationship between a 
measurable quantity and a theoretical quantity, and show that the proposed substitute 
measurable quantity is, generally, an effective surrogate for the theoretical TCP.  
 
This novel formulation will be applicable as a measure of treatment success, in situations, 
for instance, where a biopsy of tumour cells is performed, and using cell detection 
protocols, the level of control of the biomarker positive cells is determined. From this, the 
level of overall tumour control can be inferred, and the radiation therapy adjusted to 
reach the therapeutic target computed by the theoretical TCP. In this way, using the 
measurable quantity of the control of the biomarker positive cells, the theoretical TCP 
can be estimated, and the goals of therapy can be accomplished with greater efficacy. 
 
Additionally, for tumours with small numbers of cells, such as micro-metastases or those 
grown in vitro, the formulation of the TCP derived in this work will be of great benefit. 
In these cases, stochastic effects dominate, and thus, the TCP becomes a significant 
quantity in determining radiation dosing. Again, using data about the tumour in the form 
of the level of control of the biomarker positive cells at various time points along the 
course of the treatment, the theoretical TCP can be inferred, thus guiding the therapeutic 
protocol. 
 
The practical application of the TCP, in a clinical setting, centres on its use in predicting 
treatment outcomes, comparing different treatment schedules. When used in conjunction 
with an appropriate model for the normal tissue complication probability (NTCP), the 
TCP can be used to determine an optimal radiation dose.  
 
Materials and methods 
 
The mathematical details concerning the full derivation and proof of the computation of 
both the theoretical and measurable TCP can be found in the Supplementary Information 
document. Here we present a short description of these techniques. 
 
With the goal of developing a fully stochastic model for tumour growth and treatment by 
radiation, we first define a hierarchy of the critical cell populations within a tumour that 
are central for further analysis in a manner similar to Turner and Kohandel (2010). We 
consider three populations, stem S, progenitor P, and mature M, cells. Fundamentally, 
stem cells differentiate into progenitor cells, which differentiate into mature cells, or 
. However, we note that while stem cells have the capacity for unlimited 
division, progenitor cells divide only a limited number of times, and mature cells do not 
divide. Thus, we assume that a progenitor cell divides exactly N  times before finally 
differentiating into a mature cell M . That is, we have the modified hierarchy 
MPPS N  1 .  Additionally, we note that any type of cell may be killed by 
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the radiation, and we assume that it occurs with rate i, for mpsi ,, , representing stem, 
progenitor, and mature cells, respectively. Now, for the model, the following division and 
apoptosis pathways are active, with the rates for each type of division as follows (note 
that 1321  rrr  and Ni ,,1 ): 
 
 
 
Where s  and ip  refer to the birth rates for stem and progenitor cells, respectively, and 
1r , r2 and r3 refer to the probabilities of each type of stem cell division. For the purposes 
of this model, as well as the subsequent analysis, we assume that cell deaths are 
independent of one another. 
 
In order to compute the TCP, we must first define the joint probability function for the 
system. That is, we must define the probability that the system contains a given number 
of each type of cell at the time t . We make the assumption that at the initial time t0, the 
number of each type of cell is known and these values are denoted n0S ,n0P1 ,...,n0PN ,nM , 
for stem cells, each of the generations of progenitor cells, and mature cells, respectively.  
 
We then proceed by defining a set of functions that give the probability for each possible 
combination of cells in each class, at any time. Using these functions, we derive a set of 
Master equations defined as the derivatives of these functions with respect to time. This 
information is used to isolate the function giving the probability of having eradicated all 
stem cells at a given time, which we can solve for analytically, thereby deriving the 
theoretical TCP. Using an analogous procedure, we obtain a differential equation 
defining the function representing the TCP for control of the biomarker positive cells (i.e. 
S,P1,P2,...,Pk). This differential equation can be solved numerically by a novel method 
based on the method of characteristics, which is a well-established differential equation 
solution method (Supplementary Information). 
 
Results 
 
The details of the model used to describe the radiation induced cell-killing (i.e. the hazard 
function) are defined in the Supplementary Information. The model is a modified version 
of the linear-quadratic (LQ) model, with the primary assumption that all cell death occurs 
directly in the interval during the irradiation treatment. Within this model, there are 
radiosensitivity parameters   and   that change based on the cell or tissue type, since 
different cells (e.g. biomarker-positive cells vs. biomarker-negative cells) have been 
shown to have different radioresponses (Baumann et al. 2008). For instance, Bao et al. 
(2006) have observed that CD133+ cells exhibit greater radioresistance than CD133- 
cells in human glioblastomas. Based on these data, following Turner et al. (2009), we 
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assume that there is a three-fold increase in the LQ radio-sensitivity parameters,   and 
 , for biomarker-negative cells as compared to biomarker-positive cells. This depicts the 
fact that not only is control of these radio-resistant biomarker-positive cells highly 
desirable, because it theoretically provides control of stem cells, but also that 
accomplishing it would take a similar amount of radiation as control of all tumour cells, 
because of this difference in the radio-sensitivities. Figure 2 provides a graphic 
visualization of this difference in radiosensitivities as it pertains to survival fractions, or 
the fraction of a given amount of cells that survive irradiation for a given dose.  
 
To illustrate the differences between using a measurable quantity as a suitable 
representative of the TCP, the TCPS (theoretical TCP) and TCPCD+ (measurable TCP) 
values were computed numerically (supplemental Information) for three distinct radiation 
schedules, and compared. In the lack of experimental data for the number of biomarker 
positive generations of progenitor cells, N , for each of the radiation treatment schedules, 
the TCPCD+ was computed for distinct cases of 1, 2, or 3 biomarker positive generations 
of progenitor cells. Using a conventional treatment schedule (2 Gy/fr, 5 fr/wk, up to 60 
Gy), from Powathil et al. (2007), we compare the TCPS and the three curves generated 
for TCPCD+, with either 1, 2, or 3 generations of progenitor cells as biomarker-positive in 
Figure 3. The results of the simulations show that fundamentally, for realistic biological 
parameters, the difference between the TCPS and TCPCD+ curves is not drastic, as the 
curves reach a significant probability all near the same time point (Figure 3). That is, if 
the TCPCD+ was used as a substitute for the TCPS, tumour control would clinically 
correspond to 1-2 extra days of radiotherapy or 2-4 Gy of additional radiation, under the 
more conservative TCPCD+ value, depending on the radiation schedule in question. These 
results are encouraging, and suggest that using the TCPCD+ as a substitute for the 
theoretical value is indeed possible, and the extra cost of tumor control using a more 
conservative estimate is marginal.  
     
Furthermore, three treatment protocols were compared directly: conventional, hyper-
fractionated, and accelerated hyper-fractionated, taken from Powathil et al. (2007). The 
radiation schedules were as follows: conventional (scheme 1): 2 Gy/fr, 5 fr/wk, up to 60 
Gy; hyper-fractionated (scheme 2): 1.2 Gy/fr, 2 fr/d, 5 d/wk, up to 60 Gy; accelerated 
hyper-fractionated (scheme 3): 1.5 Gy/fr, 2 fr/d, 5 d/wk, up to 60 Gy. The results of these 
simulations are depicted in Figures 4 and 5, it can be inferred that the TCPS curves 
obtained are qualitatively consistent with the TCPCD+ curves, further suggesting that the 
measurable quantity is sufficient to act as a clinical substitute for the theoretical TCP. 
 
It is also important to note that in the simulations considered, the effect of setting 
S  P, giving S  P, which gives a characteristic biomarker-positive cell death rate, 
is an increased separation of the TCP curves obtained for increasing numbers of 
progenitor cells in the biomarker-positive compartment. If this assumption is not made, 
then it could be assumed that stem cells are less radiosensitive than progenitor cells, 
thereby giving the result that the TCP obtained depends very heavily on this population, 
so looking at a biomarker-based TCP would be nearly identical to looking at the 
theoretical TCP, because the effect of the additional generations of early progenitor cells 
is so negligible. 
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Discussion 
 
By describing a tumor model consisting of a unidirectional hierarchy of cancer stem cell 
proliferation into progenitor cells, and subsequently into mature cells within a tumor 
(Figure 1), and modeling the evolution of this system as a stochastic process, two 
quantities were generated and subsequently analyzed. Namely, the TCPS and the TCPCD+, 
representing the probability of eradicating all CSCs and the probability of eradicating all 
biomarker-positive cells, respectively, were generated from our model via mathematical 
analysis and numerical computation. These quantities were then computed and compared 
for three different radiation therapy treatment schedules. The general conclusion is that 
the TCPCD+, representing a measurable quantity, can reliably estimate the TCPS, 
suggesting that using the TCPCD+ as a clinical substitute for the theoretical TCPS is indeed 
very feasible. 
 
The results obtained herein also provide a possible explanation in the context of certain 
contradictory experimental results obtained. Specifically, it was reported by McCord et 
al. (2009) that CD133+ glioblastoma cells isolated from two different neurosphere 
cultures did not display consistent radioresponse behaviour relative to corresponding 
CD133- cells (McCord et al. 2009). The obtained survival fraction curves showed that 
biomarker positive cells from one neurosphere culture were more radioresistant than the 
corresponding biomarker negative cells from the same tumour, but biomarker positive 
cells from a different tumour were found to be approximately the same radiosensitivity as 
biomarker negative cells from that tumour. Based on the results of this experiment, we 
hypothesize that the observed that the survival fraction (and corresponding TCP) varies, 
depending upon the proportion of stem cells contained within the biomarker positive 
compartment. From our perspective, this is explained since the biomarker positive cells 
are not necessarily a homogeneous population of cancer stem cells, but may also include 
generations of progenitor cells with a different radiosensitivity, so that the survival 
fraction curve for the biomarker positive cells can lie anywhere between the two survival 
fraction curves for a homogeneous population of stem cells only and a homogeneous 
population of progenitor cells (although the shape of the curve may not necessarily be the 
same). Thus, this observation serves as a possible explanation of the results that 
biomarker positive cells from different tumour cell lines do not necessarily give the same 
survival fraction curve because they do not necessarily consist entirely of the same 
proportion of stem cells, even through all cells in both samples are biomarker positive. In 
fact, the survival curve obtained can be rationalized as a form of a weighted (non-
arithmetic) average of radiosensitivities of the two tumour cell subpopulations that can be 
classified as biomarker-positive. 
 
While the results obtained in this work represent a novel computational approach to 
calculate the TCP, and add a measurable, experimentally quantifiable aspect to it (namely 
the TCPCD+), an unaddressed limitation of the TCP is that it neglects to account for 
spatial effects within the tumour microenvironment that have been shown to contribute 
greatly to its radioresponse. One specific future direction in exploring this avenue of 
research would be to extend the presented model to include the effects of the oxygen 
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enhancement ratio (Wouters and Brown 1997, Dasu et al. 2005, Powathil et al. 2011). 
Because the presence of oxygen is critical in radiobiology due to its role in the formation 
of free radicals, the rate of radiation-induced cell killing is highly dependent upon it. That 
is, within a clinical context, the OER would account for the effects of a hypoxic 
microenvironment and the changes in radiosensitivity of tumour cells. Using this data in 
conjunction with the TCP model would allow for the TCP to take into account spatial 
effects, by adjusting for local oxygen availability and distribution. The extension in this 
direction is primarily motivated by current research suggesting that the tumour 
microenvironment plays a key role in determining the properties of stem cells, and their 
corresponding radioresponse. 
 
Another avenue for this research would be to combine the results presented here with 
previously studied compartment methods, such as the active-quiescent model (Maler and 
Lutscher 2010, Dhawan et al. 2013), to take full advantage of the radiobiological data. 
Doing so would allow for an even more accurate, and possibly clinically applicable 
formulation of the TCP, since factors not taken into account within the presented model, 
such as cell phase within the cell cycle, could be accounted for. 
 
Finally, an alternative, experimental research direction is to quantify the effects of the 
radiotherapy, specifically by using the tools presented above to analyze the TCP by 
observable means. Doing so would require the generation of survival curves, and from 
this curve fitting to obtain radiosensitivity parameters. Using the results of such 
experiments would enable clinicians to utilize more clinically relevant parameters, and 
thereby improve the applicability of the results presented, ultimately improving patient 
outcomes (Baumann et al. 2009). 
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List of Figure Captions 
 
Figure 1: The images, adapted from Singh et al. (2003), show that CD133+ tumor cells 
can proliferate in culture as non-adherent spheres, whereas CD133- tumor cells are not 
able to proliferate and form spheres. We assume that CSCs and early progenitors (from 
non-CSC compartment) share the CD133 biomarker. Here S, Pi ( i 1,...,N), and M 
denote stem, progenitors and mature cells, respectively. 
 
Figure 2: A graph showing a comparison of the survival fraction, as a function of a single 
dose for biomarker-positive and biomarker-negative cells, assuming a three-fold increase 
in the radio-sensitivity parameters   and   for biomarker-negative cells as compared to 
positive cells. 
 
Figure 3: A panel showing a comparison for the measurable TCP curves when 3k , for 
scheme 1 (conventional therapy), scheme 2 (hyper-fractionated therapy), and scheme 3 
(accelerated hyper-fractionated therapy), noting that there is qualitative agreement with 
the theoretical TCP curves. The right graph is for TCP as a function of time in days, and 
the left is a for TCP as a function of dose of radiaton administered. 
 
Figure 4: A panel showing a comparison for the theoretical TCP curves, for scheme 1 
(conventional therapy), scheme 2 (hyperfractionated therapy), and scheme 3 (accelerated 
hyperfractionated therapy), noting that there is qualitative agreement with the measurable 
TCP curves. The right graph is for TCP as a function of time in days, and the left is a for 
TCP as a function of dose of radiaton administered. 
 
Figure 5: A panel showing a comparison for the measurable and theoretical TCP curves 
for 3,2,1,0k , for the conventional therapy (scheme 1), noting that as k is increased, a 
slight shift occurs in the TCP curve. The right graph is for TCP as a function of time in 
days, and the left is a for TCP as a function of dose of radiaton administered. 
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Supplementary Information
1 Mathematical Model
With the goal of developing a fully stochastic model for tumor growth and treatment by
radiation, we first define a hierarchy of the heterogenous cell populations within a tumor
that are central for further analysis. Following Refs. [1, 2], we consider three populations,
stem S, progenitor P , and mature M cells. Fundamentally, stem cells differentiate into
progenitor cells, which differentiate into mature cells, or S → P → M . However, we note
that while stem cells have the capacity for unlimited division, progenitor cells divide only a
limited number of times, and mature cells do not divide. Thus, we assume that a progenitor
cell divides exactly N times before finally differentiating into a mature cell M . That is, we
have the modified hierarchy S → P1 → . . . → PN → M [1, 2]. Additionally, we note that
any type of cell may be killed due to radiation, and we assume that it occurs with rate Γi,
for i = s, p,m, representing stem, progenitor, and mature cells, respectively. The model
includes the following division pathways (note that r1 + r2 + r3 = 1, and i = 1, . . . , N):
S → S + S : ρsr1 Pi → Pi+1 + Pi+1 : ρpi
S → S + P1 : ρsr2 PN →M +M : ρpN
S → P1 + P1 : ρsr3 Pi → ∅ : Γp
S → ∅ : Γs M → ∅ : Γm
Here ρs and ρpi refer to the proliferation rates for stem and progenitor cells, respectively,
and r1, r2, r3 refer to the probabilities of each type of stem cell division (symmetric self-
renewal, asymmetric self-renewal, or symmetric commitment). For the purposes of this
model, as well as the subsequent analysis, we assume that the cell deaths are independent
of one another.
In order to compute the TCP, we first define the joint probability function for the system.
That is, we define the probability that the system contains a given number of each type of
cell at the time t [3]. We make the assumption that at the initial time t0, the number of
each type of cell is known and these values are denoted n0S, n
0
P1
, . . . , n0PN , n
0
M , for stem cells,
each of the generations of progenitor cells, and mature cells, respectively. We denote this
probability function by pnS ,nP1 ,nP2 ,...,nPN ,nM (t). The corresponding master equation [3] is then
given by:
1
dp
dt
= pnS−1ρsr1(nS − 1) + ρsr2nSpnP1−1
+ ρsr3(nS + 1)pnS+1,nP1−2 + Γs(nS + 1)pnS+1
− (ρs + Γs)nSp
+
N−1∑
i=1
ρPi(nPi + 1)pnPi+1,nPi+1−2
+
N−1∑
i=1
(nPi + 1)pnPi+1Γp − (ρPi + Γp)nPip
+ ρPN (nPN + 1)pnPN+1,nM−2 − ρPNnPNp
+ Γm(nM + 1)pnM+1 − ΓmnMp . (1)
We have omitted indices of p(t) that remain unchanged for brevity. The initial condition is
given by (δi,j is the Kronecker delta function):
pnS ,nP1 ,nP2 ,...,nPN ,nM (t0) = δnS ,n0SδnP1 ,n0P1
. . . δnPN ,n
0
PN
δnM ,n0M . (2)
From this, we can obtain master equations for the probability functions for the number
of stem cells only, as well as for the number of marker-positive cells (S, P1, P2, . . ., Pk).
Denoting the probability function for the number of stem cells, as unS(t), we observe that,
by definition:
unS(t) =
∑
nP1 ,...,nPN ,nM≥0
pnS ,nP1 ,nP2 ,...,nPN ,nM (t)
Thus we obtain
dunS
dt
= unS−1ρsr1(nS − 1)
− unSnS(ρsr1 + ρsr3 + Γs)
+ unS+1(ρsr3 + Γs)(nS + 1) , (3)
with the initial condition unS(t0) = δnS ,n0S . Following Van Kampen [3], and Zaider and
Minerbo [5], we solve for unS(t) analytically by introducing the generating function U(s, t) =∞∑
i=0
ui(t)s
i. We then obtain the following partial differential equation(PDE) for U(s, t):
∂U
∂t
− ∂U
∂s
(s− 1)(ρsr1s− ρsr3 − Γs) = 0 . (4)
This PDE can be solved via the method of characteristics [4], along with the initial condition
U(s, 0) = sn
0
S . Assuming that all parameters are constant, we obtain
U(s, t) =
[
(s− 1)(ρsr3 + Γs)e(ρs(r1−r3)−Γs)t − ρsr1s+ ρsr3 + Γs
(s− 1)(ρsr1)e(ρs(r1−r3)−Γs)t − ρsr1s+ ρsr3 + Γs
]n0S
. (5)
2
From this, we observe that the probability that there are no stem cells remaining at time t
is given by
U(0, t) =
[
(ρsr3 + Γs)e
(ρs(r1−r3)−Γs)t − ρsr3 − Γs
(ρsr1)e(ρs(r1−r3)−Γs)t − ρsr3 − Γs
]n0S
. (6)
We thus define this quantity to be the theoretical TCP, denoted TCPS(t).
Using the same technique, we can obtain the probability function for the number of
marker positive cells, denoted vnS ,nP1 ,...,nPk (t). We have:
vnS ,nP1 ,...,nPk (t) =
∑
nPk+1 ,...,nPN ,nM≥0
pnS ,nP1 ,nP2 ,...,nPN ,nM (t) . (7)
This gives (where again we have omitted the indices which remain unchanged, for brevity):
dv
dt
= vnS−1ρsr1(nS − 1) + ρsr2nSvnP1−1
+ ρsr3(nS + 1)vnS+1,nP1−2
+ Γs(nS + 1)vnS+1 − (ρs + Γs)nSv
+
k−1∑
i=1
ρPi(nPi + 1)vnPi+1,nPi+1−2
+
k−1∑
i=1
(nPi + 1)vnPi+1Γp − (ρPi + Γp)nPiv
+ (Γp + ρPk)(vnPk+1(nPk + 1)− vnPk) . (8)
The initial condition is vnS ,nP1 ,...,nPk (t0) = δnS ,n0SδnP1 ,n0P1
. . . δnPk ,n
0
Pk
. To solve for v(t), similar
to the previous case, we introduce the generating function,
V (xS, x1, . . . , xk, t) =
∑
iS ,i1,...,ik≥0
viS ,i1,...,ik(t)x
iS
S x
i1
1 . . . x
ik
k . (9)
We can obtain the following PDE for V (xS, x1, . . . , xk, t):
∂V
∂xS
(
x2Sρsr1 − (ρs + Γs − ρsr2x1)xS
)
+
∂V
∂xS
(
ρsr3x
2
1 + Γs
)
+
(
k−1∑
l=1
∂V
∂xl
(
ρPlx
2
l+1 − (ρPl + Γp)xl + Γp
))
+
∂V
∂xk
(Γp + ρPk)(1− xk) =
∂V
∂t
, (10)
with the initial condition V (xS, x1, . . . , xk, 0) = x
n0S
S x
n0P1
1 . . . x
n0Pk
k . This PDE can be numeri-
cally solved via a modified method of characteristics, which is outlined in Dhawan et al. [6].
3
2 Results
The model defining the effects of radiation on the cell populations is essentially the same as
that defined in [7]. Other model parameters were taken from [8], except for βs, βp, which were
calculated from data collected in [7], and ω, which was estimated specifically for glioblastoma
treatment. The parameters used are as follows: ρs = 0.6931 (1/day), ρp = ρpi = 0.6931
(1/day), r1 = 0.15, r2 = 0.7, r3 = 0.15, αs = 0.2 Gy
−1, βs = 0.02 Gy−2, αp = 0.2 Gy−1,
βp = 0.02 Gy
−2, n0S = 100, n
0
P1
= 100, n0P2 = 100, n
0
P3
= 100, ω = 15 min. The hazard
function, a function describing radiation-induced cell death, is based on the linear-quadratic
(LQ) model for cell survival for each dose fraction [5]. Thus, the hazard function for an
individual dose fraction of radiation, with dose d and irradiation period ω, takes value:
fj(t, d) =
(αj + 2βjd) · d
ω
, (11)
during the period of irradiation (0 ≤ t ≤ ω), and for all t > ω or t < 0, is identically 0 (with
j = s, p). Using this, we define the overall function describing the rate of cell death for the
entire treatment, consisting of all dose fractions as:
Γj(t) =
∑
i
fj(t− ti, di) , j = s, p . (12)
In the above expressions, αs, αp, βs, βp are parameters describing the radiosensitivities of
stem (s) and progenitor (p) cells in the LQ model, ti is the time of the i
th fraction, di is the
dose administered on the ith fraction, and the sum is over all fractions administered.
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